CCCC
CCCC
NASDAQ · Biotechnology

C4 Therapeutics Inc

$2.41
-0.21 (-8.02%)
As of Mar 29, 10:36 PM ET ·
Financial Highlights (FY 2026)
Revenue
42.31M
Net Income
-123,592,517
Gross Margin
Profit Margin
-292.1%
Rev Growth
+5.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 39.6% 39.6%
Operating Margin -320.5% -288.5% 28.2% 22.3%
Profit Margin -292.1% -277.5% 17.7% 21.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 42.31M 40.31M 17.10M 17.57M
Gross Profit 6.77M 6.96M
Operating Income -135,615,909 -116,297,587 4.82M 3.92M
Net Income -123,592,517 -105,986,913 3.03M 3.72M
Gross Margin 39.6% 39.6%
Operating Margin -320.5% -288.5% 28.2% 22.3%
Profit Margin -292.1% -277.5% 17.7% 21.2%
Rev Growth +5.0% +5.0% +6.2% +3.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 64.70M 53.64M
Total Equity 64.52M 70.28M
D/E Ratio 1.00 0.76
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -133,330,819 -120,690,117 5.37M 5.78M
Free Cash Flow 3.54M 3.04M